Share this article on:

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

Cohen, Calvina; Wohl, Davidb; Arribas, Jose R.c; Henry, Keithd; Van Lunzen, Jane; Bloch, Markf; Towner, Williamg; Wilkins, Edmundh; Ebrahimi, Ramini; Porter, Daniellei; White, Kirsteni; Walker, Ivani; Chuck, Susani; De-Oertel, Shampai; Fralich, Toddi

doi: 10.1097/QAD.0000000000000169
Clinical Science

Objectives: To compare the safety and efficacy of the two single-tablet regimens (STRs), rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF), in HIV-1-infected, treatment-naive adults.

Design: This is a phase 3b, randomized, open-label, multicenter, international, 96-week study.

Methods: Participants were randomized 1 : 1 to receive either RPV/FTC/TDF or EFV/FTC/TDF. The primary endpoint was the proportion of participants with HIV-1 RNA less than 50 copies/ml at week 48 by the Snapshot algorithm.

Results: A total of 786 participants were randomized. RPV/FTC/TDF was noninferior to EFV/FTC/TDF (85.8 vs. 81.6%) at week 48 for HIV-1 RNA less than 50 copies/ml [difference 4.1%, 95% confidence interval (CI) −1.1 to 9.2%]. A statistically significant difference in efficacy favoring RPV/FTC/TDF was demonstrated for participants with baseline HIV-1 RNA 100 000 copies/ml or less [(n = 510) 88.8% RPV/FTC/TDF vs. 81.6% EFV/FTC/TDF (difference 7.2%, 95% CI 1.1–13.4%)]. In participants with baseline HIV-1 RNA more than 100 000 copies/ml (n = 276), RPV/FTC/TDF demonstrated noninferior efficacy compared with EFV/FTC/TDF (79.9 vs. 81.7%, respectively, difference −1.8%, 95% CI −11.1 to 7.5%). In the RPV/FTC/TDF arm, more virologic failure was observed as baseline HIV-1 RNA levels increased. There were more participants with emergent resistance in the RPV/FTC/TDF arm than in the EFV/FTC/TDF arm (4 vs. 1%, respectively). There were fewer discontinuations because of adverse events with RPV/FTC/TDF (2.5%) than with EFV/FTC/TDF (8.7%).

Conclusion: In treatment-naive participants, RPV/FTC/TDF demonstrated noninferior efficacy and improved tolerability compared with EFV/FTC/TDF, as well as a statistically significant difference in efficacy for participants with baseline HIV-1 RNA 100 000 copies/ml or less at week 48.

Supplemental Digital Content is available in the text

aCommunity Research Initiative of New England, Boston, Massachusetts

bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

cHospital La Paz, Madrid, Spain

dHIV Program Hennepin County Medical Center, Minneapolis, Minnesota, USA

eUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany

fHoldsworth House Medical Practice, Darlinghurst, New South Wales, Australia

gDepartment of Infectious Disease, Kaiser Los Angeles Medical Center, Los Angeles, California, USA

hNorth Manchester General Hospital, Manchester, UK

iGilead Sciences, Foster City, California, USA.

Correspondence to Todd Fralich, MD, 333 Lakeside Drive, Foster City, CA 94404, USA. Tel: +1 650 524 3000; e-mail: todd.fralich@gilead.com

Received 15 August, 2013

Revised 28 November, 2013

Accepted 28 November, 2013

Meetings at which parts of the data have been presented: Cohen C, Wohl D, J Arribas J, et al. STaR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is noninferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults; 11–15 November 2012; Glasgow, UK [abstract 0425].

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

© 2014 Lippincott Williams & Wilkins, Inc.